The ACT II trial rand omized patients with T1-T4, N0/N+ SCC anal cancer to 5-FU-based CRT and cisplatin versus MMC with or without additional maintenance chemotherapy, consisting of two additional cycles of 5-FU/cisplatin following CRT (50.4 Gy in 28 fx). Were there differences in outcome or benefit with maintenance chemotherapy?